



Penile Metastasis as Unusual Presentation of Testicular Non-Seminomatous Germ Cell Tumor

Guida A^{1*}, Pipitone S^{1*}, Noventa S², Vitale MG³, Cascinu S¹ and Sabbatini R³

¹University of Modena and Reggio Emilia, Modena, Italy

²Operative Unit of Medical Oncology, Poliambulanza Foundation, Brescia, Italy

³Policlinico of Modena University Hospital of Modena, Modena, Italy

*Both authors are contributed equally

Abstract

Penile metastasis from testicular cancer is a rare condition. To our knowledge, only 11 cases have been described in literature. Patients with non-pulmonary visceral metastases should be considered poor risk, based on the International Germ Cell Cancer Collaborative Group classification. It is debated whether penis lesion is a visceral site. With this clinical case we report our experience with a rare condition, focusing on its unusual clinical presentation, difficult prognostic assessment and identification of the best therapeutic approach.

Introduction

Penile Metastasis (PM) is an uncommon situation and only few data are available from case reports and reviews. In 1870 [1], described the first clinical case of a secondary cancer of the penis, as a consequence of colon-rectum adenocarcinoma [1]. In 2006 [2], published an exhaustive review describing clinical presentation and diagnosis of penile metastases. Among the 372 cases included in the review, only 11 cases of PM from testicular cancer were mentioned [2]. Secondary penile lesion from testicular Non-Seminomatous Germ Cell Tumors (NSGCT) is a rare condition with limited data about management. We describe an interesting case of a penile metastasis as first unusual presentation of a primitive testicular cancer.

Case Presentation

A Caucasian 45-year-old man presented to our clinic for a thickening at the base of his penis, appeared three months before. He had a negative familiar and personal history. Particularly no personal history of genitourinary pathology and of sexually transmitted disease was reported. He had no referred local surgery. Clinical examination revealed a fixed, hard, erythematous nodule, 2.5 cm in diameter, on the proximal third of the penis, without any other clinical signs or symptoms. Ultrasound scan of the penis showed diffusely thickened Corpora Cavernosae (CC). A Magnetic Resonance Imaging (MRI) revealed a single lesion measuring 35 mm x 38 mm of both CC (Figure 1: A, B). A detailed study with a total body computed Tomography (CT) revealed a single nodule in the right lung (17 mm). A fine-needle aspiration biopsy of the penile nodule indicated cohesive groups of pleomorphic epithelioid cells with prominent nucleoli, giving the concluding the diagnosis of metastasis due to germinal carcinoma. The patient underwent standard inguinal right orchiectomy. The tumor measured 1.5 cm, it was composed of embryonal carcinoma (60%), yolk sac tumor (30%) and teratoma (10%). Tunica albuginea infiltrates but does not invade, there is no vascular invasion. Most of the epididymis was replaced by moderately to poorly differentiated adeno carcinoma. Post-orchiectomy tumor markers were: AFP 267.5 ng/mL, β CGH 6529 mUI/ml, LDH 416 U/L. According to the American Joint Committee of Cancer/Union for International Cancer Control (AJCC/UICC), tumor staging was pT1a N0 M1b. Prognostic stratification for this patient, based on the International Germ Cell Cancer Collaborative Group (IGCCCG) the prognostic group was poor [3]. Patients with non-pulmonary visceral metastases should be considered poor risk. It is debated whether penis lesion is a visceral site. Anyway, four courses of BEP (cisplatin 20 mg/m² on day 1–5, etoposide 100 mg/m² on days 1–5, bleomicine 18 mg/m² on days 2, 9 and 16) every three weeks represented the standard of care for both intermediate and poor risk patients. After the administration of only one cycle of BEP tumor markers were considerably reduced: AFP 10.9 ng/mL, β CGH 105 mUI/ml, LDH 363 U/L. Only three cycles of BEP were administered, because of persistent penile infection. Prophylactics Granulocyte Colony-Stimulating Factors (G-CSF) were

OPEN ACCESS

*Correspondence:

Annalisa Guida, University of Modena and Reggio Emilia, Modena, Italy, Tel: +393203744160;

E-mail: guida.annalisa@hotmail.it

Received Date: 25 Jun 2018

Accepted Date: 11 Jul 2018

Published Date: 18 Jul 2018

Citation:

Guida A, Pipitone S, Noventa S, Vitale MG, Cascinu S, Sabbatini R. Penile Metastasis as Unusual Presentation of Testicular Non-Seminomatous Germ Cell Tumor. *Clin Oncol*. 2018; 3: 1498.

Copyright © 2018 Pipitone S. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

administrated after every cycle. At the end of systemic treatment, serum tumor markers were normalized. Penile MRI and ultrasound showed residual mass of the penis (19 mm x 23 mm x 17 mm) and CT scan described reduction of the lung lesion (5 mm). A multiple-disciplinary discussion was held as to the option of surgical removal of the residual penis disease, as strangely recommended by National and International guidelines for residual mass >1 cm [4,5]. Our patient's desire to preserve the penis was taken in account and they offered him a more strictly observation for the first one year: markers, CT scan and penile MRI every 3 months, than every 6 months. To date, the patient has been followed-up for 40 months and no progression of disease is evident.

Discussion

Penile metastasis from testicular cancer is uncommon. To our knowledge, only 11 cases have been described in literature [2]. With this clinical case we report our experience with a rare condition, focusing on its unusual clinical presentation, difficult prognostic assessment and identification of the best therapeutic approach.

Germ-cell tumor

Germ Cell Tumors (GCTs) are uncommon tumors and represent for 1% of all male tumors [6,7]. GCTs are classified as seminoma or non-seminoma. Non-seminomatous tumors often comprehend multiple cell types, including embryonal cell carcinoma, choriocarcinoma, yolk sac tumor, and teratoma. The 5-year survival for testis cancer is 98% [6,7]. The most common site of metastasis in testicular cancer is the lymph nodes in the abdomen; metastasis to the lung, liver, bones, kidney and brain is also possible [8-10]. In 56% of metastatic non-seminomatous GCTs disease there are normal tumor markers are observed [11]. In their review [2], reported that in the majority of cases Penis Metastases (PM) arise from pelvic primary tumors. Prostate and bladder cancer are the most frequent primary tumor presenting secondary penile lesions: respectively 34% and 30% of 372 penis metastases cases described in literature, followed by recto-sigmoid neoplasm 13% and kidney 8%. As mentioned above, only 11 cases (3%) arise from testicular cancer [2].

Clinical presentation and diagnosis

The most common site of secondary penile lesion is the CC (35% of cases bilateral); most rarely are in Glans Penis (GP), Urethra Penile (PU), Corpus Spongiosum (CS) [12-14]. Most commonly in duration of the penis or a cutaneous lesion are the first presentation. Pain or priapism is described, but less frequently. In 60% of metastatic penile lesion there are multiple infiltrative nodules [15]. Differential diagnosis of penile lesion includes mostly infectious disease, but also pre-malignant conditions should be considered. Among malignant lesions squamous cell carcinoma is the most common type of primary penile cancer. Other epithelial forms of penis cancer, melanoma or sarcoma are less frequent. Synchronous presentation of secondary penile lesions was observed in around one third of patients, while metachronous appearance of lesion occurs after a mean time of 18 months [16]. Ultrasonography and MRI are the gold standards for accurate evaluation of involved anatomic structures of penis. However, histological confirmation is necessary. In our clinical case the penile localization was synchronous with testicular cancer, while the other cases of penile metastasis were metachronous and with a variable interval from the diagnosis of testicular tumor (from 2,5 to 24 month). Clinical presentation represents one of the main points in our case, because about 4 months needed to discover the primary tumor in the testis. Both synchronous and asymptomatic



Figure 1: A-B. MRI at diagnosis. Penis metastasis in corpora cavernosae.

presentations certainly contributed to delayed diagnosis.

Metastatic mechanism

It is difficult to understand the mechanism of metastatic spreading to the penis. Indeed, despite the rich Vascularity of corpora cavernosae, secondary lesions of the penis are rare. We briefly listed several proposed mechanisms. Retrograde venous route: the venous drainage of penis is via three main venous systems, composed by superficial dorsal vein of penis, deep dorsal vein (retro pubic venous plexus) and deep circumflex vein, retro choral plexus and pudendal plexus. Right testicular vein opens into inferior vena cava, where both drainage venous systems are confluent. By a retrograde flow of blood, testicular malignant cells may have spread into penis venous system [14].

Retrograde lymphatic route: the lymphatic drainage of penis is from the bladder base, the posterior surface of the prostate and the lower rectum; drain into the external iliac nodes [14]. The lymphatic drainage of testis is to lumbar and para-aortic nodes. By this way malignant cells may arrive at the penile skin, then the corpora or the glans penis [14]. Hematogenous spread: it is rare, but vascular invasion is a known prognostic factor for NSGCT. Vascular invasion was originally defined as the thrombotic occlusion in blood capillary vessels [17]. The artery supply the penis originates from internal pudendal arteries while testicular artery directly emerged from aorta [14]. Direct invasion or instrumental seeding are less frequent and, however, better recognized when occur [14]. Medical interview is a crucial part in this setting. Surgical history for many common conditions, such as inguinal hernia or cryptorchidism, may suggest iatrogenic anatomic variant to understand spreading tumor way.

Management and treatment

According to IGCCCG prognostic classification, in good prognosis group of patients the 5-years OS rate is 92% [3]. In patients having intermediate prognosis features OS rate is 80% and for the poor prognosis group patients' OS rate is 48% [3]. In patients with intermediate or poor prognosis, the standard treatment is represented by chemotherapy, particularly four cycles of BEP [18]. In this subgroup of patients, complete response rate ranging from 55% to 82% [18]. VIP regimen (Cisplatin, Etoposide and Ifosfamide) can be administrated in cases of contra-indications for the use to

bleomycin, such as high risk of lung injury [3,18]. The administration of prophylactics G-CSF is indicated after every cycle of BEP [19]. In 2014 [19] published a phase III trial (GETUG 13) in patients with poor-prognosis GCT. The patients with AFP and β HCG not declined after one cycle of BEP, underwent to the administration of High-Dose Chemo Therapy (HDCT) regimen. The data suggest that first line HDCT may be effective in poor prognosis patients with slow tumor markers decline after the administration of the first cycle of BEP. HDCT consisting on the infusion of two cycles of paclitaxel (175 mg/m² day 1) and BEP plus oxaliplatin (130 mg/m² day 10), followed by other two cycles of cisplatin (100 mg/m² day 1), ifosfamide (2 g/m² on days 10, 12, 14 and mesna), and bleomycin (25 units/day, by continuous infusion for 5 days on day 10 to 14), with G-CSF support. The study met his primary endpoint: 5-year PFS rate was 60% in the HDCT arm versus 47% in the BEP arm (HR 0.65; 95% CI 0.47–0.97; p=0.037). Salvage chemotherapy rate was lower in HDCT treated patients (17% vs. 8%; p=0.035) [20]. This approach is still not widely accepted, cause of lacking similar data and the reproducibility of tumor markers decline algorithm.

Surgical residual mass

After the administration of three or four cycles of cisplatin-based chemotherapy, only 60% patients show radiological complete response disease, more than 30% had partial response with the presence of residual masses [21]. The prognosis of this patients depended to serum tumour marker levels, dimensions of disease before systemic treatment, and histological features of the resected masses [22-24]. The presence of residual masses <1.5 cm, masses reduction \geq 90% after chemotherapy, and the absence of teratoma component in the primitive testicular tumour are predictive of necrosis or fibrosis [22-24]. Several trials showed histologic discordance between Retro Peritoneal (RP) and Extra-Retro Peritoneal (ERP) post-chemotherapy residual masses [22,25]. Histological features of residual mass were necrosis or fibrosis in 45% to 50% of cases, teratoma in 30% to 40% of cases, variable malignant cells (embryonal carcinoma, choriocarcinoma, yolk sac tumour, undifferentiated carcinoma, undifferentiated teratoma, teratoma in malignant transformation) in 10% to 20% of cases. Teratoma and variable malignant cells tumor were related to poor outcomes [26-28]. Removal of residual masses after chemotherapy in NSGCTs remains the standard of care [29]. Resection of RP residual masses has not only a curative objective but also a diagnostic rule [30,31]. The surgery can be done after four weeks at the end of chemotherapy and in men with residual masses with normal serum tumour markers levels [32]. When the primitive tumour shows components of variable malignant cells or teratoma, the aim of surgery treatment is radical excision of residual disease [32]. In fact, teratoma is chemo resistant; it is very aggressive because it may infiltrate adjacent structures [25]. *Devillè et al.* retrospective analysed 51 men underwent surgery after chemotherapy for metastatic NSGCT. Patients with elevated levels of AFP at diagnosis, showed mature teratoma and/or viable malignant cells in residual masses (p: 0.036). Worse outcome was reported in poor prognosis group according to IGCCCG compared with good and intermediate prognosis groups (p: 0.006) [29]. *Steynberg et al.* suggested that the resection of RP residual disease was indicated when tumoral mass reductions after chemotherapy was more than 70% and residual tumoral mass was more than 1 cm to CT-scan [33]. *Carver et al.* reported that poor prognostic risk according to IGCCCG classification and dimension of residual masses were predictive of disease recurrence in patients with residual teratoma at RP lymph

node dissection [34]. ERP metastasis is presents in 43% of patients affected of GCT [35]. ERP residual disease is related to poor prognosis if compared to retroperitoneal disease [25]. The most common location of disease recurrence was in the lung, followed by the neck and mediastinum [36-38]. In cases of surgical completely resection of residual disease, mature teratoma or necrosis/fibrosis relapsed less of 10% patients; when in residual disease were found viable malignant cells, the possibility of relapse was around 30% patients before the first 2 years [29]. When residual disease was mature teratoma or variable malignant cells, the administration of two cycles of cisplatin-based chemotherapy (after the surgery) reduced the risks of relapse and improved the PFS and OS [30,31,39].

Follow up

After treatments, men with metastatic NSGCT should be followed for early detection and treatment of relapse. There are no a clear management of this patients. According National and International guidelines, it's indicated a follow-up visit for at least the first 5 years [4,5]. For non-semimoma stage I, clinical examination, serum markers and chest-XR are recommended every 2-3 months for the first two years and every 4-6 months from third and fifth year; abdomen-pelvic CT scan are recommended every 6 months for the first two years and once a year from third and fourth year as clinical indicated [4,5,40]. In metastatic setting, the follow-up schedule provides for a clinical examination, serum markers, and every 2-3 months for the first two year and every six months from third and fifth year. Chest-XR and CT scan every six months for the first two years. CT scan should be done once a year for the third year. Chest-XR should be done once a year from third to fourth year [4,5,40].

Conclusion

To our knowledge, there are limited published data in the literature about non-seminomatous testicular cancer with metastatic localization to corpora cavernosae of penis. It's interesting to observe that in our patient, penis metastases were the first evidence of neoplastic disease with any systemic symptoms. Despite the poor prognosis, after more than 3 years of the end of chemotherapy, he was asymptomatic without clinical evidence of neoplastic disease.

References

1. CJE. Krehmetastasen des corpus cavernosum penis. *Virch Arch* 51. 1870;145.
2. Cherian J, Sreekumar Rajan, Ali Thwaini, Yaser Elmasry, Tariq Shah, Rajiv Puri. Secondary penile tumours revisited. *Int Semin Surg Oncol.* (2006);3:33.
3. International Germ Cell Cancer Collaborative Group. Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. *International Germ Cell Cancer Collaborative Group. J Clin Oncol.* 1997;15(2):594-603.
4. Linee guida AIOM Tumori del testicolo. 2013.
5. NCCN clinical practice guidelines in oncology: testicular cancer. (2013). Siegel RL, Miller KD, J.A. *Cancer statistics.* CA Cancer J Clin. 2016.
6. Bethesda. SEER Cancer Statistics Factsheets: Testis Cancer. *Natl. Cancer Institute.* 2016.
7. Johnson DE, Appelt G, Samuels ML, Luna M. Metastases from testicular carcinoma Study of 78 autopsied cases. *Urology.* 1976;8(3):234-9.
8. Donohue JP, Zachary JM, Maynard BR. Distribution of nodal metastases in nonseminomatous testis cancer. *J Urol.* 1982;128(2):315-20.

9. Bredaal JJ, Vugrin D, Whitmore WF. Autopsy findings in 154 patients with germ cell tumors of the testis. *Cancer*. 1982;50(3):548-51.
10. Schmoll HJ, Souchon R, Krega S, Albers P, Beyer J, Kollmannsberger C, et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). *Ann Oncol*. 2004;15(9):1377-99.
11. Abeshouse BS, Abeshouse GA. Metastatic tumors of the penis: a review of the literature and a report of two cases. *J Urol*. 1961;86:99-112.
12. Mikuz G. Tumors of the Prostate Gland, Seminal Vesicles, Male Urethra, and Penis. *Atlas of Tumor Pathology: Third Series, Fascicle 28*. Young RH, Srigley JR, Amin MB, Ulbright TM, Cubilla AL. Armed Forces Institute of Pathology, Washington, DC, 2000. *J Pathol*. 2001;195:638.
13. Paquin AJ, Roland SI. Secondary carcinoma of the penis; A review of the literature and a report of nine new cases. *Cancer*. 1956;9(3):626-32.
14. Osther PJ, Løntoft E. Metastasis to the penis. Case reports and review of the literature. *Int Urol Nephrol*. 1991;23(2):161-7.
15. Pomara G, Pastina L, Simone M, Casale P, Marchetti G, Francesca F. Penile metastasis from primary transitional cell carcinoma of the renal pelvis: first manifestation of systemic spread. *BMC Cancer*. 2004;4:90.
16. Howell TH. William Harvey's report on Old Parr's autopsy. *Age Ageing*. 1987;16(4):265-6.
17. Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ. Medical treatment of advanced testicular cancer. *JAMA* 2008;299(6):672-84.
18. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, et al. 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: an Evidence-Based Clinical Practice Guideline. *J Clin Oncol*. 2006;24(19):3187-205.
19. Fizazi K, Pagliaro L, Laplanche A, Fléchon A, Mardiak J, Geoffrois L, et al. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): A phase 3, multicentre, randomised trial. *Lancet Oncol*. 2014;15(13):1442-50.
20. Gerl A, Clemm C, Schmeller N, Dienemann H, Weiss M, Kriegmair M, et al. Sequential resection of residual abdominal and thoracic masses after chemotherapy for metastatic non-seminomatous germ cell tumours. *Br J Cancer*. 1994;70(5):960-5.
21. Donohue JP, Rowland RG, Kopecky K, Steidle CP, Geier G, Ney KG, et al. Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer. *J Urol*. 1987;137(6):1176-9.
22. Sheinfeld J, Bajorin D, Solomon M. Management of post chemotherapy residual masses in advanced germ cell tumors. *AUA Updat Ser*. 1997;17:18-24.
23. Bajorin DF, Herr H, Motzer RJ, Bosl GJ. Current perspectives on the role of adjunctive surgery in combined modality treatment for patients with germ cell tumors. *Semin Oncol*. 1992;19(2):148-58.
24. Katz MH, McKiernan JM. Treatment of non-retroperitoneal residual germ cell tumor masses. *Urol. Oncol*. 2005;23(6):431-9.
25. Fossà SD, Qvist H, Stenwig AE, Lien HH, Ous S, Giercksky KE. Is postchemotherapy retroperitoneal surgery necessary in patients with non-seminomatous testicular cancer and minimal residual tumor masses? *J Clin Oncol*. 1992;10(4):569-73.
26. Stenning SP, Parkinson MC, Fisher C, Mead GM, Cook PA, Fossa SD, et al. Postchemotherapy residual masses in germ cell tumor patients: content, clinical features, and prognosis. Medical Research Council Testicular Tumour Working Party. *Cancer*. 1998;83(7):1409-19.
27. Gerl A, Clemm C, Schmeller N, Dienemann H, Lamerz R, Kriegmai M, et al. Outcome analysis after post-chemotherapy surgery in patients with non-seminomatous germ cell tumours. *Annals of oncology*. 1995;6(5):483-488.
28. Deville JL, Gravis G, Salem N, Savoie PH, Esterni B, Walz J, et al. Resection of residual masses after chemotherapy for advanced non-seminomatous germ cell tumours, A monocentric analysis of pre-operative prognosticators. *Eur J Cancer Care (Engl)*. 2010;19(6):827-32.
29. Einhorn LH, Williams SD, Mandelbaum I, Donohue JP. Surgical resection in disseminated testicular cancer following chemotherapeutic cytoreduction. *Cancer*. 1981.
30. Fox EP, Weathers TD, Williams SD, Loehrer PJ, Ulbright TM, Donohue JP, et al. Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. *J Clin Oncol*. 1993;11(7):1294-9.
31. Melchior D, Müller SC, Albers P. Extensive surgery in metastatic testicular cancer. *Aktuelle Urol*. 2003;34(4):214-22.
32. Steyerberg EW, Keizer HJ, Fossà SD, Sleijfer DT, Bajorin DF, Donohue JP, et al. Resection of residual retroperitoneal masses in testicular cancer: evaluation and improvement of selection criteria. The ReHiT study group. Re-analysis of histology in testicular cancer. *Br J Cancer*. 1996;74(9):1492-8.
33. Carver BS, Shayegan B, Serio A, Motzer RJ, Bosl GJ, Sheinfeld J. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma. *J Clin Oncol*. 2007;25(9):1033-7.
34. Carver BS, Serio AM, Bajorin D, Motzer RJ, Stasi J, Bosl GJ, et al. Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors. *J Clin Oncol*. 2007;25(35):5603-8.
35. Stomper PC, Jochelson MS, Garnick MB, Richie JP. Residual abdominal masses after chemotherapy for nonseminomatous testicular cancer: Correlation of CT and histology. *AJR Am J Roentgenol*. 1985;145(4):743-6.
36. Carter GE, Lieskovsky G, Skinner DG, Daniels JR. Reassessment of the role of adjunctive surgical therapy in the treatment of advanced germ cell tumors. *J Urol*. 1987;138(6):1397-401.
37. Stephenson AJ, Sheinfeld J. The role of retroperitoneal lymph node dissection in the management of testicular cancer. *Urologic Oncology: Seminars and Original Investigations*. 2004;22(3):225-233.
38. Fizazi K, Tjulandin S, Salvioni R, Germà-Lluch JR, Bouzy J, Ragan D, et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group. *J Clin Oncol*. 2001;19(10):2647-57.
39. Van As NJ, Gilbert DC, Money-Kyrle J, Bloomfield D, Beesley S, Dearnaley DP, et al. Evidence-based pragmatic guidelines for the follow-up of testicular cancer: Optimising the detection of relapse. *Br J Cancer*. 2008;98(12):1894-902.